Recent studies have demonstrated that aspirin improves NAFLD and reduces the risk of HCC in NAFLD patients by inhibiting lipid biosynthesis and inflammation and increasing catabolism via activation of the PPARδ-AMPK-PGC-1α pathway [104,105]. The gene discussed is PPARGC1A; the disease is metabolic dysfunction-associated steatotic liver disease.